大葉大學圖書館 |

Cancer drug discovery[electronic resource] :science and history /

レコード種別:	言語・文字資料 (印刷物) : 単行資料
[NT 15000414] null:	615.798
タイトル / 著者:	Cancer drug discovery : science and history // by Kyu-Won Kim ... [et al.].
その他の著者:	Kim, Kyu-Won.
出版された:	Dordrecht : : Springer Netherlands :, 2016.
記述:	xvii, 276 p. : : ill., digital ;; 24 cm.
含まれています:	Springer eBooks
主題:	Biomedicine.
主題:	Cancer Research.
主題:	Pharmacy.
主題:	History of Medicine.
主題:	Antineoplastic agents - Development.
主題:	Cancer - Chemotherapy.
国際標準図書番号 (ISBN) :	9789402408447
国際標準図書番号 (ISBN) :	9789402408423
[NT 15000228] null:	Part Ⅰ. A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1 Characteristics of cancer cells -- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part Ⅱ. Cancer Drug Discovery - Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1 A historical background of cancer chemotherapy -- 3.2 Development of the anticancer drug screening systems -- 3.3 Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4. Alkylating Anticancer Drugs -- 4.1 Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1 Plant-derived anticancer drugs -- 6.2 Anticancer antibiotics -- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1 Immunotherapeutic anticancer drugs -- 7.2 Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9. Molecular Targeted Anticancer Drugs -- 9.1 Tretinoin (all-trans retinoic acid, ATRA) -- 9.2 Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4 HER2 inhibitors -- 9.5 Angiogenesis inhibitors -- 9.6 Other kinase inhibitors -- 9.7 mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9 Epigenetic anticancer drugs -- 9.10 Proteasome inhibitors -- 9.11 Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part Ⅲ. A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs.
[NT 15000229] null:	This book describes the history of cancer drugs development to provide insight into the successes and the shortcomings of this enterprise. Most cancer drug treatments target the cancer cell as the core component and as such are very effective in inhibiting their proliferation. However, these cancer drugs are generally ineffective against metastasis, which are tightly linked to the whole body as a system. This book illustrates the problems in cancer drug design and suggests a more systemic view of cancer with a more adapted research approach. The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs, which has been deeply influenced by the 'cell concept' of cancer. Future directions for the development of new anticancer drugs will also be presented. This book has been separated into three sections, providing an overview of: - The scientific progress in the biological sciences over the last 60 years and the influence this progress has had in cancer research. Summaries and charts of important discoveries complete this overview - The process of anticancer drug development with a focus on the characteristic drug groups of each era, illustrated by comprehensive timelines and conceptual cartoons - The limitations of the current cancer drug development pipelines and the new directions for cancer drug discovery, considering a more systemic view of cancer This book is a useful reference for scientists and clinicians working in the biomedical field and for oncologists aiming to explore the landscape of human endeavor in the fight against cancer.
電子資源:	http://dx.doi.org/10.1007/978-94-024-0844-7

Cancer drug discovery[electronic resource] :science and history /
Cancer drug discoveryscience and history /[electronic resource] :by Kyu-Won Kim ... [et al.]. - Dordrecht :Springer Netherlands :2016. - xvii, 276 p. :ill., digital ;24 cm.

Part Ⅰ. A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1 Characteristics of cancer cells -- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part Ⅱ. Cancer Drug Discovery - Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1 A historical background of cancer chemotherapy -- 3.2 Development of the anticancer drug screening systems -- 3.3 Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4. Alkylating Anticancer Drugs -- 4.1 Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1 Plant-derived anticancer drugs -- 6.2 Anticancer antibiotics -- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1 Immunotherapeutic anticancer drugs -- 7.2 Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9. Molecular Targeted Anticancer Drugs -- 9.1 Tretinoin (all-trans retinoic acid, ATRA) -- 9.2 Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4 HER2 inhibitors -- 9.5 Angiogenesis inhibitors -- 9.6 Other kinase inhibitors -- 9.7 mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9 Epigenetic anticancer drugs -- 9.10 Proteasome inhibitors -- 9.11 Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part Ⅲ. A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs.

This book describes the history of cancer drugs development to provide insight into the successes and the shortcomings of this enterprise. Most cancer drug treatments target the cancer cell as the core component and as such are very effective in inhibiting their proliferation. However, these cancer drugs are generally ineffective against metastasis, which are tightly linked to the whole body as a system. This book illustrates the problems in cancer drug design and suggests a more systemic view of cancer with a more adapted research approach. The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs, which has been deeply influenced by the 'cell concept' of cancer. Future directions for the development of new anticancer drugs will also be presented. This book has been separated into three sections, providing an overview of: - The scientific progress in the biological sciences over the last 60 years and the influence this progress has had in cancer research. Summaries and charts of important discoveries complete this overview - The process of anticancer drug development with a focus on the characteristic drug groups of each era, illustrated by comprehensive timelines and conceptual cartoons - The limitations of the current cancer drug development pipelines and the new directions for cancer drug discovery, considering a more systemic view of cancer This book is a useful reference for scientists and clinicians working in the biomedical field and for oncologists aiming to explore the landscape of human endeavor in the fight against cancer.

ISBN: 9789402408447

Standard No.: 10.1007/978-94-024-0844-7doiSubjects--Topical Terms:

463454
Biomedicine.

LC Class. No.: RS431.A64

Dewey Class. No.: 615.798

Cancer drug discovery[electronic resource] :science and history /
LDR:05191nam a2200313 a 4500 001 476392
003 DE-He213
005 20161114141448.0
006 m d
007 cr nn 008maaau
008 181208s2016 ne s 0 eng d
020 $a 9789402408447 $q (electronic bk.)
020 $a 9789402408423 $q (paper)
024 7 $a 10.1007/978-94-024-0844-7 $2 doi
035 $a 978-94-024-0844-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RS431.A64
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 615.798 $2 23
090 $a RS431.A64 $b C215 2016
245 0 0 $a Cancer drug discovery $h [electronic resource] : $b science and history / $c by Kyu-Won Kim ... [et al.].
260 $a Dordrecht : $b Springer Netherlands : $b Imprint: Springer, $c 2016.
300 $a xvii, 276 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part Ⅰ. A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1 Characteristics of cancer cells -- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part Ⅱ. Cancer Drug Discovery - Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1 A historical background of cancer chemotherapy -- 3.2 Development of the anticancer drug screening systems -- 3.3 Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4. Alkylating Anticancer Drugs -- 4.1 Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1 Plant-derived anticancer drugs -- 6.2 Anticancer antibiotics -- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1 Immunotherapeutic anticancer drugs -- 7.2 Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9. Molecular Targeted Anticancer Drugs -- 9.1 Tretinoin (all-trans retinoic acid, ATRA) -- 9.2 Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4 HER2 inhibitors -- 9.5 Angiogenesis inhibitors -- 9.6 Other kinase inhibitors -- 9.7 mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9 Epigenetic anticancer drugs -- 9.10 Proteasome inhibitors -- 9.11 Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part Ⅲ. A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs.
520 $a This book describes the history of cancer drugs development to provide insight into the successes and the shortcomings of this enterprise. Most cancer drug treatments target the cancer cell as the core component and as such are very effective in inhibiting their proliferation. However, these cancer drugs are generally ineffective against metastasis, which are tightly linked to the whole body as a system. This book illustrates the problems in cancer drug design and suggests a more systemic view of cancer with a more adapted research approach. The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs, which has been deeply influenced by the 'cell concept' of cancer. Future directions for the development of new anticancer drugs will also be presented. This book has been separated into three sections, providing an overview of: - The scientific progress in the biological sciences over the last 60 years and the influence this progress has had in cancer research. Summaries and charts of important discoveries complete this overview - The process of anticancer drug development with a focus on the characteristic drug groups of each era, illustrated by comprehensive timelines and conceptual cartoons - The limitations of the current cancer drug development pipelines and the new directions for cancer drug discovery, considering a more systemic view of cancer This book is a useful reference for scientists and clinicians working in the biomedical field and for oncologists aiming to explore the landscape of human endeavor in the fight against cancer.
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Cancer Research. $3 463530
650 2 4 $a Pharmacy. $3 343916
650 2 4 $a History of Medicine. $3 427931
650 0 $a Antineoplastic agents $x Development. $3 403962
650 0 $a Cancer $x Chemotherapy. $3 382675
700 1 $a Kim, Kyu-Won. $3 687112
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-94-024-0844-7
950 $a Biomedical and Life Sciences (Springer-11642)